BACKGROUND: Monoclonal antibodies may be used more effectively in combination. A previous study of intravenous (iv) bolus alemtuzumab plus rituximab in patients with chronic lymphocytic leukemia (CLL) recurrence produced a response rate of 54% after a 4-week treatment period. METHODS: To optimize dose, schedule, and route of alemtuzumab, a study was designed exploring continuous intravenous infusion (civ) followed by subcutaneous (sc) alemtuzumab together with weekly iv rituximab in patients with previously treated CLL. RESULTS: Data from 40 patients with a median age of 59 years, and a median of 3 prior regimens (range, 1-8 regimens) were evaluable. Approximately 64% of patients were fludarabine-refractory. Seven patients (18%) achieved a complete response (CR), 4 (10%) a nodular partial response (nPR), and 10 (25%) a partial response for an overall response rate of 53%. Of 11 major responses (CR, nPR), 8 occurred after cycle 1. Response rates were highest in blood (94%), followed by liver/spleen (82%), bone marrow (68%), and lymph nodes (51%). The combination did not generate unexpected toxicities. Cytomegalovirus (CMV) reactivations occurred in 6 patients (15%) and responded well to anti-CMV therapy. High titers of anti-idiotype antibodies after sc alemtuzumab were demonstrated in 1 patient, but remained without clinical sequelae. CONCLUSIONS: The combination of civ/sc alemtuzumab plus rituximab has activity in some patients with recurrent/refractory CLL and maximum response is achieved after 1 cycle (4 weeks) in 73% of patients. Further exploration in other settings of CLL together with accompanying pharmacokinetic studies is recommended. (c) 2010 American Cancer Society.
BACKGROUND: Monoclonal antibodies may be used more effectively in combination. A previous study of intravenous (iv) bolus alemtuzumab plus rituximab in patients with chronic lymphocytic leukemia (CLL) recurrence produced a response rate of 54% after a 4-week treatment period. METHODS: To optimize dose, schedule, and route of alemtuzumab, a study was designed exploring continuous intravenous infusion (civ) followed by subcutaneous (sc) alemtuzumab together with weekly iv rituximab in patients with previously treated CLL. RESULTS: Data from 40 patients with a median age of 59 years, and a median of 3 prior regimens (range, 1-8 regimens) were evaluable. Approximately 64% of patients were fludarabine-refractory. Seven patients (18%) achieved a complete response (CR), 4 (10%) a nodular partial response (nPR), and 10 (25%) a partial response for an overall response rate of 53%. Of 11 major responses (CR, nPR), 8 occurred after cycle 1. Response rates were highest in blood (94%), followed by liver/spleen (82%), bone marrow (68%), and lymph nodes (51%). The combination did not generate unexpected toxicities. Cytomegalovirus (CMV) reactivations occurred in 6 patients (15%) and responded well to anti-CMV therapy. High titers of anti-idiotype antibodies after sc alemtuzumab were demonstrated in 1 patient, but remained without clinical sequelae. CONCLUSIONS: The combination of civ/sc alemtuzumab plus rituximab has activity in some patients with recurrent/refractory CLL and maximum response is achieved after 1 cycle (4 weeks) in 73% of patients. Further exploration in other settings of CLL together with accompanying pharmacokinetic studies is recommended. (c) 2010 American Cancer Society.
Authors: Michael J Keating; Ian Flinn; Vinay Jain; Jacques-Louis Binet; Peter Hillmen; John Byrd; Maher Albitar; Lee Brettman; Pedro Santabarbara; Bret Wacker; Kanti R Rai Journal: Blood Date: 2002-05-15 Impact factor: 22.113
Authors: Maher Albitar; Kim-Anh Do; Marcella M Johnson; Francis J Giles; Iman Jilani; Susan O'Brien; Jorge Cortes; Deborah Thomas; Laura Z Rassenti; Thomas J Kipps; Hagop M Kantarjian; Michael Keating Journal: Cancer Date: 2004-09-01 Impact factor: 6.860
Authors: Gerard Lozanski; Nyla A Heerema; Ian W Flinn; Lisa Smith; Jennifer Harbison; Jennifer Webb; Mollie Moran; Margaret Lucas; Thomas Lin; Marcy L Hackbarth; John H Proffitt; David Lucas; Michael R Grever; John C Byrd Journal: Blood Date: 2004-01-15 Impact factor: 22.113
Authors: Geoff Hale; Peppy Rebello; Lee R Brettman; Chris Fegan; Ben Kennedy; Eva Kimby; Mike Leach; Jeanette Lundin; Håkan Mellstedt; Paul Moreton; Andy C Rawstron; Herman Waldmann; Anders Osterborg; Peter Hillmen Journal: Blood Date: 2004-04-15 Impact factor: 22.113
Authors: Clive S Zent; Timothy G Call; Tait D Shanafelt; Renee C Tschumper; Diane F Jelinek; Deborah A Bowen; Charla R Secreto; Betsy R Laplant; Brian F Kabat; Neil E Kay Journal: Cancer Date: 2008-10-15 Impact factor: 6.860
Authors: Stefan Faderl; Deborah A Thomas; Susan O'Brien; Guillermo Garcia-Manero; Hagop M Kantarjian; Francis J Giles; Charles Koller; Alessandra Ferrajoli; Srdan Verstovsek; Barbara Pro; Michael Andreeff; Miloslav Beran; Jorge Cortes; William Wierda; Ngoc Tran; Michael J Keating Journal: Blood Date: 2003-01-09 Impact factor: 22.113
Authors: Alessandra Ferrajoli; William G Wierda; Ruth LaPushin; Susan M O'Brien; Stefan Faderl; Mary L Browning; Michael J Keating Journal: Eur J Haematol Date: 2007-12-21 Impact factor: 2.997
Authors: Xavier C Badoux; Michael J Keating; Xuemei Wang; Susan M O'Brien; Alessandra Ferrajoli; Stefan Faderl; Jan Burger; Charles Koller; Susan Lerner; Hagop Kantarjian; William G Wierda Journal: Blood Date: 2011-06-13 Impact factor: 22.113
Authors: Ingo Schubert; Christian Kellner; Christoph Stein; Markus Kügler; Michael Schwenkert; Domenica Saul; Kristin Mentz; Heiko Singer; Bernhard Stockmeyer; Wolfgang Hillen; Andreas Mackensen; Georg H Fey Journal: MAbs Date: 2011-01-01 Impact factor: 5.857